Portal de Periódicos da CAPES

Treatment with Cabergoline Is Associated with Weight Loss in Patients with Hyperprolactinemia

2003; Wiley; Volume: 11; Issue: 2 Linguagem: Inglês

10.1038/oby.2003.46

1550-8528

Judith Körner, Janet Lo, Pamela U. Freda, Sharon L. Wardlaw,

Adrenal Hormones and Disorders

Obesity ResearchVolume 11, Issue 2 p. 311-312 Free Access Treatment with Cabergoline Is Associated with Weight Loss in Patients with Hyperprolactinemia Judith Korner M.D., Ph.D, Corresponding Author Judith Korner M.D., Ph.D Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York E-mail: jk181@columbia.edu Department of Medicine, Division of Endocrinology, Columbia University College of Physicians & Surgeons, 630 West 168th Street, Black Building, Room 905, New York, New York 10032. E-mail: jk181@columbia.eduSearch for more papers by this authorJanet Lo, Janet Lo Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York E-mail: jk181@columbia.eduSearch for more papers by this authorPamela U. Freda, Pamela U. Freda Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York E-mail: jk181@columbia.eduSearch for more papers by this authorSharon L. Wardlaw, Sharon L. Wardlaw Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York E-mail: jk181@columbia.eduSearch for more papers by this author Judith Korner M.D., Ph.D, Corresponding Author Judith Korner M.D., Ph.D Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York E-mail: jk181@columbia.edu Department of Medicine, Division of Endocrinology, Columbia University College of Physicians & Surgeons, 630 West 168th Street, Black Building, Room 905, New York, New York 10032. E-mail: jk181@columbia.eduSearch for more papers by this authorJanet Lo, Janet Lo Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York E-mail: jk181@columbia.eduSearch for more papers by this authorPamela U. Freda, Pamela U. Freda Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York E-mail: jk181@columbia.eduSearch for more papers by this authorSharon L. Wardlaw, Sharon L. Wardlaw Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York E-mail: jk181@columbia.eduSearch for more papers by this author First published: 06 September 2012 https://doi.org/10.1038/oby.2003.46Citations: 21AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat To the Editor: Cabergoline is a new long-acting dopamine receptor agonist that is usedfor the treatment of hyperprolactinemic disorders. Binding studies showthat cabergoline has high affinity for dopamine D2 receptors and lowaffinity for dopamine D1, α1- and α2-adrenergic, and 5-HT1- and5-HT2-serotonin receptors. After noting weight loss in a number ofpatients treated with cabergoline for hyperprolactinemia in ourNeuroendocrine Unit, we conducted a retrospective chart review todetermine the effect of cabergoline on body weight in this population. Patients with panhypopituitarism or previously treated with anotherdopamine agonist were excluded. Of the 27 patients who met thesecriteria, initial and follow-up body weights were available for 16patients (10 men; 6 women), and height measurements used to calculatebody mass index were available for 13 patients. Mean initial bodyweight ± SEM was 86.1 ± 5.0 kg, and initial body mass indexwas 30.0 ± 1.6 kg/m2. The mean dose ofcabergoline was a total of 0.92 ± 0.14 mg per week, and the meanduration of therapy was 13.5 ± 1.7 months. The mean change inweight was −6.1 ± 1.4 kg (p < 0.001 by pairedStudent's t test of initial and final weights). Of the 16patients, 13 patients lost weight, 1 remained stable, and 2 gainedweight (Figure 1). The mean percentage of change in body weight was −7.0 ± 1.5%:five patients lost 5% to 10% and four patients lost >10% of initialbody weight. Of the 16 patients, 10 reported side effects that could beattributable to cabergoline: dizziness, n = 3;fatigue/sleepiness, n = 3; nausea, n =3; paresthesias/tremor, n = 2; depression,n = 2; headache, n = 1; and vomiting,n = 1. Symptoms resolved within the first few weeks oftherapy without a change in dosage, except in one case when the dosewas reduced from 1 mg to 0.5 mg twice per week with resolution ofdizziness and nausea. Figure 1Open in figure viewerPowerPoint : Change in body weight for 16 patients on cabergoline for hyperprolactinemia. Symbols indicate weekly dose: ♦, ≤0.5 mg; ▵, ≥1.0 and <2.0 mg; •, ≥2.0 mg. Solid line: men. Dashed line: women. The contribution of the dopaminergic system to the regulation of bodyweight has been difficult to elucidate because of the presence ofmultiple receptor subtypes throughout the nervous system and theeffects of dopamine on motor activity. Weight loss has been reported inobese leptin deficient ob/ob mice after dopamineadministration ((1)), and weight gain with administration ofdopamine antagonists in rodents and humans ((2))((3)). On theother hand, dopamine-deficient mice are hypophagic ((4)), and dopamine is required for hyperphagia in ob/ob mice((5)). These apparently discrepant results are indicative ofthe complex role of dopamine in food intake. There is some evidence that hyperprolactinemia is associated withobesity and that patients with prolactinomas treated withbromocriptine, another D2 receptor agonist, lose weight((6)). Others have studied the effects on body weight of aquick release form of bromocriptine in patients without prolactinomas, but the results of these studies have been variable, and interpretationis complicated because of differences in study design and adverseeffects of nausea and vomiting ((7))((8))((9)). This is the firstreport to date that notes a weight loss effect from cabergolinetreatment. Cabergoline is longer acting and better tolerated thanbromocriptine ((10)). The results of this study suggest thatcabergoline may be an effective weight reduction therapy, and the useof this medication for the treatment of obesity warrants furtherinvestigation. References 1 Bina, K. G., Cincotta, A. H. (2000) Dopaminergic agonists normalize elevatedhypothalamic neuropeptide Y and corticotropin-releasing hormone, bodyweight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 71: 68– 78. CrossrefCASPubMedWeb of Science®Google Scholar 2 Lacruz, A., Baptista, T., de Mendoza, S., Mendoza-Guillen, J. M., Hernandez, L. (2000) Antipsychotic drug-induced obesity in rats: correlation betweenleptin, insulin and body weight during sulpiride treatment. MolPsychiatry 5: 70– 6. CASPubMedWeb of Science®Google Scholar 3 Allison, D. B., Casey, D. E. (2001) Antipsychotic-induced weight gain: a reviewof the literature. J Clin Psychiatry 62: 22– 31. CASPubMedWeb of Science®Google Scholar 4 Szczypka, M. S., Rainey, M. A., Kim, D. S., et al. (1999) Feeding behavior indopamine-deficient mice. Proc Natl Acad Sci USA 96: 12138– 43. CrossrefCASPubMedWeb of Science®Google Scholar 5 Szczypka, M. S., Rainey, M. A., Palmiter, R. D. (2000) Dopamine is required forhyperphagia in Lepob/ob mice. Nat Genet 25: 102– 4. CrossrefCASPubMedWeb of Science®Google Scholar 6 Greenman, Y., Tordjman, K., Stern, N. (1998) Increased body weight associatedwith prolactin secreting pituitary adenomas: weight loss withnormalization of prolactin levels. Clin Endocrinol 48: 547– 53. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar 7 Cincotta, A. H., Meier, A. H. (1996) Bromocriptine (Ergoset) reduces body weightand improves glucose tolerance in obese subjects. Diabetes Care 19: 667– 70. CrossrefPubMedWeb of Science®Google Scholar 8 Kamath, V., Jones, C. N., Yip, J. C., et al. (1997) Effects of a quick-release formof bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetichyperinsulinemic women. Diabetes Care 20: 1697– 701. CrossrefCASPubMedWeb of Science®Google Scholar 9 Pijl, H., Ohashi, S., Matsuda, M., et al. (2000) Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 23: 1154– 1161. CrossrefCASPubMedWeb of Science®Google Scholar 10 Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., Scanlon, M. F. (1994) A comparison of cabergoline and bromocriptine in the treatmentof hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331: 904– 9. CrossrefCASPubMedWeb of Science®Google Scholar Citing Literature Volume11, Issue2February 2003Pages 311-312 FiguresReferencesRelatedInformation